Targeted therapy for biliary-tract cancer.
Furuse
Junji
J
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001661:Biliary Tract Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D019275:Radiopharmaceuticals; D003841:Deoxycytidine; D019788:Fluorodeoxyglucose F18; D000068258:Bevacizumab